Trade Generation Bio Co. - GBIO CFD

Add to favourite

2.75

6.46%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.05

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Generation Bio Co ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	2.94
Open*	2.98
1-Year Change*	-32.88%
Day's Range*	2.75 - 2.98
52 wk Range	0.86-7.35
Average Volume (10 days)	391.47K
Average Volume (3 months)	17.23M
Market Cap	116.30M
P/E Ratio	-100.00K
Shares Outstanding	66.08M
Revenue	3.03M
EPS	-1.98
Dividend (Yield %)	N/A
Beta	2.60
Next Earnings Date	Feb 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	2.75	-0.23	-7.72%	2.98	2.98	2.72
Apr 17, 2024	2.94	-0.15	-4.85%	3.09	3.10	2.83
Apr 16, 2024	3.10	-0.46	-12.92%	3.56	3.57	3.10
Apr 15, 2024	3.67	0.03	0.82%	3.64	3.68	3.39
Apr 12, 2024	3.68	-0.26	-6.60%	3.94	4.04	3.58
Apr 11, 2024	3.96	0.37	10.31%	3.59	4.01	3.59
Apr 10, 2024	3.68	-0.17	-4.42%	3.85	3.99	3.62
Apr 9, 2024	3.96	-0.38	-8.76%	4.34	4.50	3.92
Apr 8, 2024	4.33	0.38	9.62%	3.95	4.40	3.95
Apr 5, 2024	3.93	-0.06	-1.50%	3.99	4.11	3.87
Apr 4, 2024	4.01	-0.13	-3.14%	4.14	4.24	3.91
Apr 3, 2024	4.11	0.12	3.01%	3.99	4.23	3.98
Apr 2, 2024	4.09	0.04	0.99%	4.05	4.21	3.89
Apr 1, 2024	4.27	0.13	3.14%	4.14	4.61	3.97
Mar 28, 2024	4.06	0.37	10.03%	3.69	4.27	3.69
Mar 27, 2024	3.67	0.43	13.27%	3.24	3.70	3.19
Mar 26, 2024	3.15	0.02	0.64%	3.13	3.30	3.13
Mar 25, 2024	3.19	-0.05	-1.54%	3.24	3.38	3.13
Mar 22, 2024	3.31	0.11	3.44%	3.20	3.45	3.15
Mar 21, 2024	3.32	0.11	3.43%	3.21	3.38	3.14

Generation Bio Co. Events

Time (UTC)	Country	Event
Wednesday, May 8, 2024
Time (UTC) 10:59	Country US	Event Q1 2024 Generation Bio Co Earnings Release Q1 2024 Generation Bio Co Earnings Release Forecast - Previous -
Friday, June 7, 2024
Time (UTC) 13:00	Country US	Event Generation Bio Co Annual Shareholders Meeting Generation Bio Co Annual Shareholders Meeting Forecast - Previous -
Wednesday, July 31, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 Generation Bio Co Earnings Release Q2 2024 Generation Bio Co Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	0	0	0	0	0.036
Revenue				0	0.036
Total Operating Expense	141.182	119.101	81.114	62.302	37.33
Selling/General/Admin. Expenses, Total	44.464	33.854	22.582	12.168	9.178
Research & Development	90.918	85.247	58.532	50.134	28.152
Operating Income	-141.182	-119.101	-81.114	-62.302	-37.294
Interest Income (Expense), Net Non-Operating	4.543	-0.05	0.591	0.985	1.491
Net Income Before Taxes	-136.639	-119.151	-80.523	-61.317	-35.803
Net Income After Taxes	-136.639	-119.151	-80.523	-61.317	-35.803
Net Income Before Extra. Items	-136.639	-119.151	-80.523	-61.317	-35.803
Net Income	-136.639	-119.151	-80.523	-61.317	-35.803
Income Available to Common Excl. Extra. Items	-136.639	-119.151	-80.523	-61.317	-35.803
Income Available to Common Incl. Extra. Items	-136.639	-119.151	-80.523	-61.317	-35.803
Diluted Net Income	-136.639	-119.151	-80.523	-61.317	-35.803
Diluted Weighted Average Shares	58.1149	56.2954	46.2919	57.6958	57.6958
Diluted EPS Excluding Extraordinary Items	-2.35119	-2.11653	-1.73946	-1.06276	-0.62055
Dividends per Share - Common Stock Primary Issue				0	0
Diluted Normalized EPS	-2.25139	-2.11653	-1.73946	-1.06276	-0.62055
Unusual Expense (Income)	5.8

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0.88	0	0	0	0
Total Operating Expense	34.799	34.866	34.688	32.669	38.481
Selling/General/Admin. Expenses, Total	12.967	12.866	13.081	11.477	10.116
Research & Development	21.832	22	20.807	21.192	23.365
Operating Income	-33.919	-34.866	-34.688	-32.669	-38.481
Interest Income (Expense), Net Non-Operating	2.853	2.772	2.283	1.363	0.552
Net Income Before Taxes	-31.066	-32.094	-32.405	-31.306	-37.929
Net Income After Taxes	-31.066	-32.094	-32.405	-31.306	-37.929
Net Income Before Extra. Items	-31.066	-32.094	-32.405	-31.306	-37.929
Net Income	-31.066	-32.094	-32.405	-31.306	-37.929
Income Available to Common Excl. Extra. Items	-31.066	-32.094	-32.405	-31.306	-37.929
Income Available to Common Incl. Extra. Items	-31.066	-32.094	-32.405	-31.306	-37.929
Diluted Net Income	-31.066	-32.094	-32.405	-31.306	-37.929
Diluted Weighted Average Shares	65.6562	60.2301	59.4207	58.8723	57.1495
Diluted EPS Excluding Extraordinary Items	-0.47316	-0.53286	-0.54535	-0.53176	-0.66368
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.47316	-0.53286	-0.53189	-0.53176	-0.57619
Unusual Expense (Income)			0.8		5
Revenue	0.88

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	287.016	379.186	267.735	18.156	76.926
Cash and Short Term Investments	279.091	375.145	262.327	15.076	74.87
Cash & Equivalents	93.171	375.145	62.889	15.076	7.305
Short Term Investments	185.92	0	199.438	0	67.565
Total Receivables, Net	0.395		0	0.448	1.288
Accounts Receivable - Trade, Net	0.395		0	0.448	1.288
Prepaid Expenses	7.53	4.041	5.408	2.577	0.714
Other Current Assets, Total			0	0.055	0.054
Total Assets	376.264	476.771	294.155	42.14	83.519
Property/Plant/Equipment, Total - Net	81.423	91.029	23.781	21.845	4.486
Property/Plant/Equipment, Total - Gross	95.961	101.045	29.443	24.075	4.875
Accumulated Depreciation, Total	-14.538	-10.016	-5.662	-2.23	-0.389
Other Long Term Assets, Total	7.825	6.556	2.639	2.139	2.107
Total Current Liabilities	19.15	18.808	11.22	9.158	6.555
Accounts Payable	0.662	2.023	0.267	2.251	1.681
Accrued Expenses	18.062	16.109	8.862	5.218	3.958
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	0.426	0.676	2.091	1.689	0.916
Total Liabilities	93.771	95.025	26.142	25.139	9.517
Total Long Term Debt	0	0	0	0	0
Other Liabilities, Total	74.621	76.217	14.922	15.981	2.962
Total Equity	282.493	381.746	268.013	17.001	74.002
Redeemable Preferred Stock	0	0	0	115.822	115.822
Preferred Stock - Non Redeemable, Net				-0.229	-0.229
Common Stock	0.006	0.006	0.005	0.001	0.001
Additional Paid-In Capital	727.335	689.866	456.974	9.859	5.552
Retained Earnings (Accumulated Deficit)	-444.765	-308.126	-188.975	-108.452	-47.135
Other Equity, Total	-0.083	0	0.009	0	-0.009
Total Liabilities & Shareholders’ Equity	376.264	476.771	294.155	42.14	83.519
Total Common Shares Outstanding	59.5054	56.9696	46.2919	57.6958	57.6958

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	297.809	320.623	344.733	287.016	310.558
Cash and Short Term Investments	291.025	314.143	288.649	279.091	301.169
Cash & Equivalents	93.36	144.97	95.65	93.171	134.487
Short Term Investments	197.665	169.173	192.999	185.92	166.682
Prepaid Expenses	6.124	6.14	6.77	7.53	8.994
Total Assets	381.492	404.883	431.417	376.264	402.799
Property/Plant/Equipment, Total - Net	76.79	77.802	79.975	81.423	84.561
Other Long Term Assets, Total	6.893	6.458	6.709	7.825	7.68
Total Current Liabilities	32.819	26.479	22.737	19.15	17.318
Accounts Payable	2.65	2.328	1.504	0.662	1.693
Accrued Expenses	17.825	15.48	14.967	18.062	15.255
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	12.344	8.671	6.266	0.426	0.37
Total Liabilities	149.578	150.596	152.278	93.771	94.05
Total Long Term Debt	0	0	0	0	0
Other Liabilities, Total	116.759	124.117	129.541	74.621	76.732
Total Equity	231.914	254.287	279.139	282.493	308.749
Redeemable Preferred Stock	0	0	0	0
Common Stock	0.007	0.007	0.007	0.006	0.006
Additional Paid-In Capital	768.102	762.228	755.957	727.335	721.405
Retained Earnings (Accumulated Deficit)	-536.191	-507.925	-476.859	-444.765	-412.36
Other Equity, Total	-0.004	-0.023	0.034	-0.083	-0.302
Total Liabilities & Shareholders’ Equity	381.492	404.883	431.417	376.264	402.799
Total Common Shares Outstanding	65.928	65.7842	65.5357	59.5054	59.2752
Total Receivables, Net	0.66	0.34	49.314	0.395	0.395
Accounts Receivable - Trade, Net	0.66	0.34	1.814	0.395	0.395
Property/Plant/Equipment, Total - Gross	95.224	94.944	95.802	95.961	98.063
Accumulated Depreciation, Total	-18.434	-17.142	-15.827	-14.538	-13.502

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-136.639	-119.151	-80.523	-61.317	-35.803
Cash From Operating Activities	-102.448	-91.821	-70.142	-40.346	-28.119
Cash From Operating Activities	5.13	4.532	3.432	1.864	0.347
Non-Cash Items	28.015	18.623	8.661	3.88	2.654
Changes in Working Capital	1.046	4.175	-1.712	15.227	4.683
Cash From Investing Activities	-192.515	193.047	-205.196	47.985	-69.761
Capital Expenditures	-8.801	-5.958	-5.518	-19.986	-3.021
Other Investing Cash Flow Items, Total	-183.714	199.005	-199.678	67.971	-66.74
Cash From Financing Activities	12.989	214.671	323.095	0.078	100.189
Financing Cash Flow Items	-0.631	-0.955	-3.226	-0.022	0
Issuance (Retirement) of Stock, Net	13.62	215.626	326.321	0.1	100.189
Net Change in Cash	-281.974	315.897	47.757	7.717	2.309

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-32.094	-136.639	-104.234	-72.928	-34.999
Cash From Operating Activities	-27.677	-102.448	-79.445	-58.968	-35.435
Cash From Operating Activities	1.33	5.13	3.784	2.42	1.197
Non-Cash Items	4.189	28.015	23.044	17.582	6.094
Changes in Working Capital	-1.102	1.046	-2.039	-6.042	-7.727
Cash From Investing Activities	-5.616	-192.515	-174.119	-161.505	-2.784
Capital Expenditures	-0.755	-8.801	-8.119	-7.468	-2.784
Other Investing Cash Flow Items, Total	-4.861	-183.714	-166	-154.037	0
Cash From Financing Activities	35.772	12.989	12.906	3.593	0.052
Financing Cash Flow Items	-0.228	-0.631	-0.444	-0.05	-0.05
Issuance (Retirement) of Stock, Net	36	13.62	13.35	3.643	0.102
Net Change in Cash	2.479	-281.974	-240.658	-216.88	-38.167

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Generation Bio Co. Company profile

About Generation Bio Co

Generation Bio Co. is genetic medicines to provide treatments of rare and prevalent diseases. The Company through its non-viral genetic medicine platform, is engaged in developing genetic medicines to provide genetic payloads, which include large and multiple genes to a range of cell types across a range of diseases. It is comprised of three component technologies: ceDNA, ctLNP and ceDNA manufacturing process. ceDNA is an engineered, double-stranded, linear, covalently closed-ended deoxyribonucleic acid (DNA) construct, which includes the gene of interest and associated regulatory sequences. It has produced ceDNA constructs of approximately eight kilobases. Its ctLNP delivery system builds upon clinically validated lipid nanoparticles and is designed to allow for repeat dosing of a genetic payload without stimulating an immune response, such as antibody production. Its ceDNA manufacturing process uses its own cell-free rapid enzymatic synthesis (RES) to produce ceDNA.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Generation Bio Co revenues was not reported. Net loss increased 48% to $119.2M. Higher net loss reflects alancing val increase of 39% to $51M (expense), Labor & Related Expenses in R&D increase of 43% to $24.9M (expense), Stock-based Compensation in R&D increase from $4.3M to $9.3M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.74 to -$2.12.

Industry:

Bio Therapeutic Drugs

301 Binney Street
CAMBRIDGE
MASSACHUSETTS 02142
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024